Navigation Links
Synedgen Announces Issuance of Patent to Optimize Animal Health
Date:3/22/2013

Claremont CA (PRWEB) March 22, 2013

Synedgen Inc., a bio-pharmaceutical company developing novel therapies to prevent and treat infection and inflammation, announces that the United States Patent and Trademark Office (USPTO) has issued patent claims for the use of chitosan derivatives to treat or inhibit infections, and optimize animal health and weight gain to allow for the use of lower doses of antibacterial agents in animal feed. This issuance, U.S. Patent No. 8,399,635 Chitosan derivatives to treat animals or optimize animal health, continues the expansion of Synedgen’s patent portfolio.

The full patent covers methods of inhibiting the growth of or killing of bacteria, reducing bacterial load, preventing or delaying the onset of an infection, disease or disorder in an animal subject, and includes preparation, dosage and administration methods.

“The issuance of these claims enhances the strength of our growing IP portfolio,” stated Synedgen President Shenda Baker. “It describes the utility of our chitosan derivatives for infection control in food animals as well as the ability to synergize with traditional antibiotics used in their feed, dramatically reducing the amount of antibiotic used. These claims also complement the launch of Synoplex®, Synedgen’s veterinary wound rinse product designed to treat infected, chronic and non-infected wounds in elephants and rhinoceros.”

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Cla
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
3. Probiotic Action Announces Probiotics Pending Listing on EU Foods
4. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
5. Neogen Corporation Announces 3rd Quarter Results Conference Call
6. Medifirst Solutions, Inc. Announces Further Update To Shareholders
7. Elsevier Announces the Launch of a New Journal: Wound Medicine
8. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
9. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
10. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
11. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Vernon Hills, IL (PRWEB) January 15, 2014 ... Cole-Parmer to find hard-working items for the lab, from ... designated as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
Breaking Biology Technology:Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... SHANGHAI, Sep. 4 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... Chinese firm,specializing in the manufacture, research, development, marketing ... Company,s,management team will attend the Susquehanna International Group ... The SIG 3rd Annual ...
... , AURORA, Ontario, Sept. 4 Helix BioPharma ... has accepted subscriptions for the purchase, by way of private placement, ... gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private ... unit consists of one common share and one common share purchase ...
... Kendle (Nasdaq: KNDL ), a leading, global full-service ... the upcoming Robert Baird 2009 Health Care Conference on Sept. ... New York City. , , (Logo: ... Kendle,s formal presentation will be given by Senior Vice President ...
Cached Biology Technology:China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit 2Helix BioPharma Announces $13.5 Million Private Placement 2Kendle to Present at Robert Baird 2009 Health Care Conference 2
(Date:7/10/2014)... even improve the state of fisheries resources in ... Mediterranean has deteriorated over the past 20 years. ... reported in the Cell Press journal Current ... stringent monitoring of Mediterranean fishing activities, better enforcement ... Mediterranean waters. , Their data show that the ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... company housed at NJIT,s business incubator, received a $1.4 ... surgeons will use to staunch bleeding during brain surgery. ... site, and the natural bio-polymer solutions in the gel ... 30 seconds. , The gel can shorten an ... into less time for the patient,s skull to be ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... , This release is also available in Chinese ... it the anti-sunscreen. That,s more or less the description of ... light-catching substances that could be added to photovoltaic materials in ... electricity. Research reported in the journal ...
... 2010) Autism Speaks, Chief Science Officer Geraldine ... environmental risk factors for autism spectrum disorders as ... Works, Subcommittee on Children,s Health convened a special ... autism spectrum disorders (ASD) and related neurodevelopmental disorders. ...
... for two competitive grants to better understand and manage outbreaks ... fisheries in Puget Sound. The grants cover the first year ... the next three years. NEW FORECAST ... goal of one project is to develop a forecasting ability ...
Cached Biology News:Selenium makes more efficient solar cells 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 3New research to improve management of harmful algal blooms in Puget Sound 2
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The versatile Promega Flipper® Racks are ... of your small tubes. These polypropylene racks ... choice for freezer storage. They may also ... Each rack is two-sided; one side accommodates ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: